As mentioned, the ABC-DLBCL subtype is characterized by constitutive activation of NF-κB pathway.9 Inhibitor of NF-κB signaling is toxic to ABC-DLBCL cells,25,26 To investigate whether SNS-032 treatment inhibits NF-κB signaling in ABC- and GCB-DLBCL cell lines, SU-DHL-4, and SU-DHL-2 cells were maintained with various doses of SNS-032. Here, NFKB1 is linked to diffuse large B-cell lymphoma.